Apellis Pharmaceuticals (APLS)
(Delayed Data from NSDQ)
$22.95 USD
+0.61 (2.73%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $22.95 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum A VGM
Fundamental Charts
About Dividend Yield (TTM)
Apellis Pharmaceuticals, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
APLS 22.95 +0.61(2.73%)
Will APLS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for APLS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for APLS
Apellis Pharmaceuticals (APLS) Reports Q2 Earnings: What Key Metrics Have to Say
Repligen (RGEN) Lags Q2 Earnings Estimates
APLS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Axsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Sanofi's Gene Therapy for Eye Disease Gets FDA's Fast Track Tag
Apellis Stock Rises on $300M Royalty Deal With Sobi for Aspaveli
Other News for APLS
Apellis price target raised by $4 at JPMorgan, here's why
Apellis Pharmaceuticals, Inc. (APLS) Q2 2025 Earnings Call Transcript
Apellis Pharmaceuticals, Inc. 2025 Q2 - Results - Earnings Call Presentation
Apellis (APLS) Price Target Raised as Market Stabilizes
RBC Capital Raises Price Target for Apellis Pharmaceuticals (APLS) | APLS Stock News